In the setting of advanced cancers except Hodgkin lymphoma (likely also MSI-H tumors), only the minority of cancer patients had durable response to PD-1/PD-L1 blockade monotherapy, and some patients even had disease hyperprogression. The gene discussed is CD274; the disease is Hodgkins lymphoma.